VTGN

Announcements

Nothing here yet

Daily updates

• VistaGen reported initial open-label Phase 3 PALISADE-4 extension data for fasedienol nasal spray, showing favorable tolerability with PRN use over 12 months in social anxiety disorder.Sep 23, 2026
• SRX Global acquires an equity stake in VistagenAug 4, 2026

FDA designations

Nothing here yet

News

• Vistagen reports preliminary positive data from the open-label extension of the Phase 3 PALISADE-4 study of fasedienol for acute treatment of social anxiety disorderSep 22, 2026
• Vistagen reported topline results from its repeat-dose study of fasedienol for the acute treatment of social anxiety disorderAug 6, 2026
• Vistagen reported topline and post-hoc Phase 3 PALISADE-4 results for fasedienol in social anxiety disorderJul 1, 2026
• Vistagen reports preliminary positive data from PALISADE-3 Phase 3 extension study of fasedienolMay 12, 2026
• Vistagen received an FDA 'Study May Proceed' letter for Refisolone, allowing further Phase 2 development for menopause-related hot flashesApr 22, 2026